Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $1.1 billion.

  • Catalyst Pharmaceuticals' Liabilities and Shareholders Equity rose 36.22% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year increase of 45.80%. This contributed to the annual value of $851.4 million for FY2024, which is 81.11% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $1.1 billion for Q3 2025, which was up 8.20% from $971.9 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Liabilities and Shareholders Equity peaked at $1.1 billion during Q3 2025, and registered a low of $197.2 million during Q1 2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $706.4 million (2024), whereas its average is $694.8 million.
  • Data for Catalyst Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY surged of 86.83% (in 2024) over the last 5 years.
  • Catalyst Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $237.8 million in 2021, then surged by 57.97% to $375.6 million in 2022, then increased by 25.15% to $470.1 million in 2023, then spiked by 81.11% to $851.4 million in 2024, then surged by 36.22% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $971.9 million for Q2 2025, and $908.9 million during Q1 2025.